Fig. 2
Kaplan-Meier estimates of survival for patients treated in the third line with cetuximab or BSC. BSC, best supportive care
Fig. 2 | Health Economics Review
Kaplan-Meier estimates of survival for patients treated in the third line with cetuximab or BSC. BSC, best supportive care